New attack plan for tough myeloma: immune cells + transplant shows promise
NCT ID NCT05850286
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new approach for people newly diagnosed with multiple myeloma who have a high-risk genetic change (P53 abnormality). The treatment combines standard chemotherapy with a double dose of specially engineered immune cells (CAR-T cells) and a stem cell transplant. The goal is to see if this powerful upfront therapy can lead to deep remissions and better long-term control of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-BCMA CAR-T cells (a type of immune cell therapy) combined with chemotherapy (bortezomib, lenalidomide, dexamethasone) and stem cell transplant
- What this could lead to
- If successful, this approach could offer a powerful first-line treatment option for multiple myeloma patients with high-risk P53 abnormalities, potentially leading to deep and lasting remission.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 20 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact